Appendix 2



Bwrdd Iechyd Prifysgol Bae Abertawe

Swansea Bay University Health Board


COVID-19 RISK REGISTER GOLD COMMAND 24th May 2021





Aligning Risk with Swansea Bay University Health Board (SBUHB) Strategy

The Swansea Bay University Health Board (SBUHB) strategy is outlined in the figure below and all risks identified for inclusion on the Health Board Risk Register are mapped to our enabling objectives.



COVID-19 RISK REGISTER DASHBOARD OF ASSESSED RISKS – GOLD COMMAND

	5	R_COV_004: Covid Related Sickness Absence	R_COV_008: Capacity Moved to OSG R_COV_009a: Workforce Shortages R_COV_010: Delivery of Essential Care Moved to OSG	R_COV_015a: Mass Vaccination (Medium Term) R_COV_19a: Opening of Field Hospital (revised model - December 2020)	R_COV_012: Partnership Working – <u>Moved to HBRR</u> R_COV_18: Whole-Service Closure – <u>Moved to HBRR</u>	R_COV_20: Workforce Resilience Moved to HBRR		
sednences	4	R_COV_009b: Workforce – Recruitment-Closed R_COV_013: Test, Trace and Protect Moved to TTP cell		R_COV_005: Care Homes R_COV_003: Inadequate supply of PPE R_COV_015b: Mass Vaccination (Short Term)	R_COV_17: Nosocomial Transmission Also on HBRR			
Impact/Consequences	3							
	2		R_COV_001: Shortage of Critical Care drugs Moved to Medicines Management R_COV_002: Shortage of Palliative Care drugs Moved to Medicines Management					
	1							
C	XL	1	2	3	4	5		
		Likelihood						

✤ Please note that some risks are deemed closed but may re-open if 2nd or 3rd wave occurs

COVID 19 Risk Register Dashboard

Risk Reference	Datix ID	Description of risk identified	Initial Score	Current Score	Trend	Controls	Last Reviewed	Scrutiny Committee
R_COV_001	2367	Shortage of critical care drug - Reduced from 15 to 4 Global shortages which is affecting the UK of a number of drugs/ fluids to manage patients cared for in critical care areas could restrict number of people able to be supported in critical care unit and restrict capacity to enact full COVID critical care response plan - Moved to Medicines Management	25	4	¥	→	10.05.2021	Gold Command COVID-19
R_COV_002	2368	Shortage of Palliative Care Drugs - Reduced from 15 to 4 National shortage of palliative care drugs and access to syringe drivers which could impact on ability to provide timely care for patients at home or in hospital; causing pain for patients and distress for patients and their families. Inability to access drugs for patients at home could impact on hospital sector if these patients subsequently require hospital admission. Distress for patients in families in not being able to die in their place of choice Moved to Medicines Management	25	4	¥	>	10.05.2021	Gold Command COVID-19
R_COV_003	2378	Inadequate Supply of PPE - Reduced from 15 to 12 Inadequate supply of PPE could place staff at risk of harm and an increase in the number of staff infected will increase absence rates, resulting in difficulties in staffing core capacity.	25	12	¥	→	24.05.2021	Gold Command COVID-19
R_COV_004	2369	Covid related sick absence Number of staff who are absent from work through self-isolation or family illness will impact on ability to deliver safe care for patients; and will impact on ability to keep capacity open and to staff surge and super surge capacity. NOTE This risk ONLY captures the total of staff absence as reported weekly to WG risk score reflects the position in comparison with wave one position which peaked at 1700 staff absent.	25	5	¥	•	24.05.2021	Gold Command COVID-19
R_COV_005	2370	Care Homes Potential failure in local care home sector to manage staff absences could result in emergency closure of care home which will place undue pressure and therefore on community health and social services to support and/or lead to an increase in patient admission to hospital. Risk of patient harm if care homes are not adequately covered.	25	12	¥	→	24.05.2021	Gold Command COVID-19

R_COV_006	2371	Equipment Shortages (Currently closed) Inability to secure adequate supply of equipment to support phases of capacity plan which may restrict ability of Board to respond to peaks in pandemic if not mitigated. This includes availability of ventilators, CPAP, suppliers, syringe drivers	25	10	→	¥	30.11.2020	Gold Command COVID-19
R_COV_007	2372	Oxygen Provision (Currently closed) Capacity constraints on oxygen provision at Morriston will limit number of ventilator, CPAP and high flow oxygen beds. Lack of ability to secure direct suppliers via BOC will hamper plans for oxygen provision within field hospital	25	10	→	¥	30.11.2020	Gold Command COVID-19
R_COV_008	2373	Capacity – Reduced from 20 to 10 and Moved to OSG Capacity requirements against national modelling mean that the HB capacity may be either insufficient to cope with demand of 2nd surge, resulting in an inability to care for patients as well as an increased risk of excess death.	25	10	¥	→	10.05.2021	Gold Command COVID-19
R_COV_009a	2374	Workforce Shortages Measures the risk to service provision, deployment plans and HB strategic workforce related developments i.e. surge capacity, field hospital / Imms programme in the context of the number of available staff. Factors impacting cover Covid and general sick absence, deployment restrictions relating to staff covid risk assessment, general turnover, Outbreaks. Key risk areas where specific workforce shortages impact is the greatest e.g. ITU, A&E, Covid wards are reflected in the overall score.	25	10	→	→	24.05.2021	Gold Command COVID-19
R_COV_009b	2534	Workforce Recruitment – Reduced from 8 to 4 and Closed Despite efforts to recruit staff into substantive, agency, bank and other roles the HB fails to meet the expanding requirement to replace staff covid related or increase staff resource as a consequence of new staff resource needs. The workforce staff recruitment/supply risk has been assessment NOT just against the existing HB plans which had already highlighted the HB difficulties with staffing super surge. The risk score reflects the risks with meeting every and all existing 5confirmed requirement. The risk includes the internal risk given the pressures on relatively small departments who need to support recruitment. There is significant pressure on the pool of Non registered staff in the SW of Wales with HBs and LA all recruiting from the same pool, this impacts not only on the availability but quality of candidates.	25	4	¥	¥	10.05.2021	Gold Command COVID-19

R_COV_010	2375	Delivery of Essential Care Reduced from 20 to 10 and Moved to OSG Following the guidance to step down routine activity issued by Welsh Government and the pandemic Health and Social Care Response Plan, the R&R programme was overseeing the restart of routine and essential services. Some services remain significantly under pre-covid capacity. There is a risk that the delivery of essential and routine services will be disrupted again through a 2nd peak in COVID admissions and levels of service delivery will need to be adjusted to support the covid response.	25	10	¥	→	10.05.2021	Gold Command COVID-19
R_COV_011	2376	<u>Workforce Risk assessment tool (Currently closed)</u> There is growing evidence that COVID-19 is having a disproportionate impact on individuals from BAME backgrounds. The evidence continues to evolve but the UK Intensive Care National Audit and Research Centre findings on critical care published on 24th April 2020 and the data on BAME deaths published in the Health Service Journal on 22nd April provided sufficient evidence to indicate that individuals from BAME backgrounds may be at disproportionate risk from poorer outcomes from COVID-19.	25	10	→	¥	30.11.2020	Gold Command COVID-19
R_COV_012	2377	Partnership Working Reduced from 25 to 20 and Moved to HBRR There are growing tensions between the Health Board and some trade union partners within SBUHB particularly in response to the supply of PPE which has the potential to create unrest in the workforce and hamper an effective response to COVID-19.	25	20	¥	¥	10.05.2021	Gold Command COVID-19
R_COV_013	2388	Test, Trace, Protect Reduced from 5 to 4 and Moved to TTP Cell The TTP programme is operational and staff have been recruited to both regional and local teams. There is a risk that there will be insufficient capacity locally to contend with significant or prolonger outbreaks and the sustainability of the service is a concern given the temporary nature of deploying people from core roles. There is also a risk that testing capacity may not be sufficient to deal with sudden upsurges in demand. Longer laboratory times will negatively impact on the effectiveness of contact tracing.	20	4	¥	→	10.05.2021	Gold Command COVID-19
R_COV_014	2456	Key worker support from schools Reduced from 15 to 3 (Currently closed) Both Swansea and NT Local Authorities have indicated they do not have plans to provide key worker support over the 6-week summer break. As some staff may not be able to access the support they would have normally have relied upon during this period due to Covid restriction, these staff may have no options but to remain at home to care for their children. Existing policy during the pandemic was that we did support staff in these circumstances by providing basic pay only.	15	3	→	¥	30.11.2020	Gold Command COVID-19

R_COV_015a	2457	Mass Vaccination (Medium Term) The Health Board will need to plan a mass vaccination programme for COVID- 19 vaccine alongside management of the annual influenza programme. This will present a number of challenges, including workforce availability, logistics and supply, parallel delivery with the influenza programme and the constraints around co-administration, as well as administrative and information management considerations. Planning parameters have been released by Welsh Government. The most significant risk in the delivery of the programme is in securing sufficient workforce and the availability of a digital solution that provides an end to end information system to establish the programme.	20	15	¥	→	24.05.2021	Gold Command COVID-19
R_COV_015b	TBC	<u>Mass Vaccination (Short Term) Reduced from 16 to 12</u> The Health Board will need to plan a mass vaccination programme for COVID- 19 vaccine alongside management of the annual influenza programme. This will present a number of challenges, including workforce availability, logistics and supply, parallel delivery with the influenza programme and the constraints around co-administration, as well as administrative and information management considerations. Planning parameters have been released by Welsh Government. The most significant risk in the delivery of the programme is in securing sufficient workforce and the availability of a digital solution that provides an end to end information system to establish the programme.	20	12	¥	→	24.05.2021	Gold Command COVID-19
R_COV_016	2491	Bed Spacing (Closed) Guidance was issued by WG in July setting out minimum requirements in respect of bed spacing between hospital beds. As a result of a detailed risk assessment carried out at Board level, the Board will not be able to fully comply with this guidance in respect of a minimum 3.6m mid to mid bed, and 3.7m between from bed head to middle of space across to opposite bed. This increases the potential risk of nosocomial transmission. If beds are withdrawn from use due to non-compliance with the minimum standards, then this introduces risk around the loss of capacity and potential for patient harm to be caused across the system due to flow issues.	16	12	→	¥	01.02.2021	Gold Command COVID-19
R_COV_017	2521	Nosocomial transmission Reduced to from 20 to 16 Also on HBRR Nosocomial transmission in hospitals could cause patient harm; increase staff absence and create wider system pressures (and potential for further harm) due to measures that will be required to control outbreaks.	25	16	¥	¥	24.05.2021	Gold Command COVID-19
R_COV_018	2522	Whole-Service Closure – Moved to HBRR Risk that services or facilities may not be able to function if there is a major incident or a rising tide that renders current service models unable to operate	25	20	→	→	10.05.2021	Gold Command COVID-19

R_COV_019a	2567	Opening of Field Hospital (revised model - December 2020) Risk of patient harm if the field hospital is opened without adequate assurance that the clinical and workforce models are robust and that appropriate policies and procedures are in place	25	15	¥	→	24.05.2021	Gold Command COVID-19
R_COV_019b	2568	Opening of Field Hospital (revised model - December 2020) (CLOSED) Risk of patient harm if the field hospital is opened without adequate assurance that the clinical and workforce models are robust and that appropriate policies and procedures are in place	25	20	¥	¥	20.04.2021	Gold Command COVID-19
R_COV_020	2569	Workforce Resilience (added 16/12/20) – Moved to HBRR Culmination of the pressure and impact on staff wellbeing - both physical and mental relating to Covid Pandemic. Local prevalence of Covid infections increasing positive testing and the debilitating effect of the second wave impacting staff. Impact direct in terms of covid / related sickness (symptomatic Absence) and self-isolation (Asymptomatic). Increased staff absence impact on the pressures for those still in work.	25	25	→	→	10.05.2021	Gold Command COVID-19

Datix ID Number: 2367	R_COV_Strategic_001
Risk: <u>Shortage of critical care drugs</u> Global shortages which is affecting the UK of a number of drugs/ fluids to manage patients cared for in critical care areas could restrict number of people able to be supported in critical care unit and restrict capacity to enact full COVID critical care response plan. Drugs used to manage the critical care of these patients are required in much higher doses than standard care.	Director Lead: Richard Evans, Medical Director Assuring Committee: Gold Command COVID-19 Date last reviewed: 10 th May 2021 Moved to Medicines Management Risk Register
Controls (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)
Monitoring mechanism in place for critical care drugs.	Action Lead Deadline
 Lack of hemofiltration fluids across the UK escalated to ECCW on 18/04/20. Assessment of further local contingency plan to be undertaken week beg 20th April 20 	Escalate to WG via critical care network to seek mutual aid in event of drug shortages; ongoing liaison with WG and suppliers.Clinical Director PharmacyWeekly ongoing
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis.	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.
Current Risk Rating 2 x 2 = 4 Initial Risk 25 Current 4 Target 10	Additional Comments Monitoring mechanism in place for critical care drugs. Access to priority medicines dashboard with a formalised mutual aid agreements between HBs supported by Health Courier Wales. Situation improving due to UK government working to create new supply routes alongside ongoing work to reduce waste, increase production of ready to administer medicines and the availability of unlicensed medicines. Anxiety remains about the potential of further peaks alongside the recommencing of routine care. National guidance on the essential role of medicines in recommencing routine care is expected and will reiterate the importance of organisations ensuring that any procedure which requires an anaesthetic, sedative, analgesic or neuromuscular blocker has assessed that the Medicines are available and can be replenished, if not that there are readily available substitutes and that stocks are sufficient to manage any emergency requirement for these drugs such as in the case of Covid 19. SBU pharmacy team have a four day buffer stock which will be kept to manage any emergency situation. There are ongoing discussions between DOH and pharmaceutical manufacturers to develop a 6-week buffer stock for the UK in anticipation of no deal Brexit, thus risk remains Amber currently. Discussion at Gold 28.08.20: No alteration to post-MA risk score required currently. National procurement exercise ongoing to stockpile supplies. Deadline for completion was 10.08.20. Consider revision of score once assessment is available to consider. Discussion at Gold 18.09.20: No alteration to post-MA risk score required currently. 16.10.20 - Remdesivir availability: manufacturer have signed a joint procurement agreement with EU to ensure improved availability for at least the next six months. The manufacturer has indicated that they

expect to be in a position to meet global demand by the end of Oct 2020. The position of UK and the JPA
with EU will also be monitored in the event that there is an impact resulting from Brexit arrangements in
2021. There are ongoing discussions between DOH and pharmaceutical manufacturers to develop a 6-
week buffer stock for the UK in anticipation of no deal Brexit, thus risk remains Amber currently.
Discussion at Gold 29.10.20: No alteration to post-MA risk score required currently.
Discussion at gold 06.11.20: No alteration to post-MA risk score required currently. These remain under
tight review with Brexit looming.
Discussion at Gold 13.11.20 & 23.11.20: No alteration to post-MA risk score required currently.
Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently.
Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 07.1.21: No alteration to post-MA risk score required currently.
Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently.
Discussion at Gold 01.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 15.03.21: No alteration to post-MA risk score required currently as, despite there being
no significant issues, there are unknowns in the supply chain.
Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Monitoring of issues
ongoing in case of impact on supplies to patients.
Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. JV to consider
downgrading score in light of stable position across supply.
Discussion at Gold 20.04.21: There are improvements in supply of critical care and palliative medicines.
HB Dashboard shows good stock holding and contingency stocks are available. Demand for medicines
for COVID and co-morbidities have reduced signifantly. Medicines dashboard continues to be monitored
daily. Score is downgraded to 4 from 15.
Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. RW to check with
Medicines Management Board if these risks can be closed on the COVID-19 Strategic Risk Log for
monitoring via usual Medicines Management channels.
Review 30.04.2021: The Medicines Management (MM) Team is satisfied that the risk may be removed
from the COVID-19 Strategic Risk Log. The MM Team
continues to monitor drug shortages but has not identified any immediate concerns in relation to COVID.
Drug shortages will remain on the Brexit risk log and on Datix, for now.
Discussion at Gold 10.05.2021: No alteration to post-MA risk score required -Closed on the COVID-19
Strategic Risk Log and for monitoring via usual Medicines Management channels.
Strategic Risk Log and for monitoring via usual Medicines Management channels.

Datix ID Number: 2368	R_COV_Strategic_002		
Risk: <u>Shortage of Palliative Care Drugs</u> National shortage of palliative care drugs and access to syringe drivers which could impact on ability to provide timely care for patients at home or in hospital; causing pain for patients and distress for patients and their families. Inability to access drugs for patients at home could impact on hospital sector if these patients subsequently require hospital admission. Distress for patients in families in not being able to die in their place of choice. The	Director Lead: Richard Evans, Medical Director Assuring Committee: Gold Command COVID-19 Date last reviewed: 10 th May 2021 Moved to Medicines Management Risk Register		
standard process of the just in case needs to be managed via a just in time approach.			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more shou		
 Local distribution plan now refined to be able to supply drugs at home quickly as required whilst preserving central stock. The Health Board has adopted Welsh Government guidance on the potential for re-using critical supplies in nursing homes and will follow the all Wales Standard Operating Procedure in adopting this flexibility and will put in place a review and audit mechanism 	Action Ongoing liaison with suppliers and WG to identify further supplies.	Lead Clinical Director Pharmacy	Deadline Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis. Current Risk Rating 2 x 2 = 4 Initial Risk 25 Current 4 Target 10	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service. Additional Comments Increased agility to supply limited stocks through the following Community Pharmacies (including those holding additional p. • 2nd line – The Palliative Hub at Morriston Hospital Pharmace • 3rd line – The national COVID-19 end of life medicine service • 4th Line – repurposing of medication at the care home in ac Potential no deal Brexit – DOH discussion with suppliers for 6 discussed in EPRR group. Discussion at Gold 28.08.20: No alteration to post-MA risk sc procurement exercise ongoing to stockpile supplies. Deadline Consider revision of score once assessment is available to co Discussion at Gold 18.09.20: No alteration to post-MA risk sc Discussion at Gold 22.10.20: No alteration to post-MA risk sc Discussion at Gold 22.10.20: No alteration to post-MA risk sc Discussion at Gold 23.11.20: No alteration to post-MA risk sc Discussion at Gold 30.11.20: No alteration to post-MA risk sc Discussion at Gold 30.11.20: No alteration to post-MA risk sc Discussion at Gold 30.11.20: No alteration to post-MA risk sc Discussion at Gold 11.12.20: No alteration to post-MA risk sc Discussion at Gold 21.12.20: No alteration to post-MA risk sc Discussion at Gold 21.12.20: No alteration to post-MA risk sc Discussion at Gold 21.12.20: No alteration to post-MA risk sc Discussion at Gold 21.12.20: No alteration to post-MA risk sc Discussion at Gold 21.12.20: No alteration to post-MA risk sc	alliative medicines cy Department ce (available 24/7) ccordance with the 6-week buffer. Brex core required currer e for completion wa onsider. core required currer core required currer core required currer ore required current core required current core required current core required current core required current core required current core required current	stocks) attached SOP it risk being ntly. National s 10.08.20. ntly. ntly. ntly. tly. These uired currently. ntly. ntly.

Discussion at Gold 07.01.21: No alteration to post-MA risk score required currently.
Discussion at Gold 24.01.21: No alteration to post-MA risk score required currently.
Discussion at Gold 01.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 15.03.21: No alteration to post-MA risk score required currently as, despite
there being no significant issues, there are unknowns in the supply chain.
Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Monitoring
of issues ongoing in case of impact on supplies to patients.
Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. JV to
consider downgrading score in light of stable position across supply.
Discussion at Gold 20.04.21: Risks updated and downgraded. These are still for monitoring in
light of the potential for escalation. Stocks of palliative care drugs are reporting as normal.
national end of life scheme currently being reviewed. Local processes remain available should
they be required. Score has reduced to 4 from 15.
Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. RW to
check with Medicines Management Board if these risks can be closed on the COVID-19
Strategic Risk Log for monitoring via usual Medicines Management channels.
Review 30.04.2021: The Medicines Management (MM) Team is satisfied that the risk may be
removed from the COVID-19 Strategic Risk Log. The MM Team
continues to monitor drug shortages but has not identified any immediate concerns in relation
to COVID. Drug shortages will remain on the Brexit risk log and on Datix, for now.
Discussion at Gold 10.05.2021: No alteration to post-MA risk score required -Closed on the
COVID-19 Strategic Risk Log and for monitoring via usual Medicines Management channels.

Datix ID Number: 2378	R_COV_Strategic_003					
Risk: <u>Inadequate Supply of PPE</u> Inadequate supply of PPE could place staff at risk of harm and an increase in the number of staff infected will increase absence rates, resulting in difficulties in staffing core capacity.	Director Lead: Christine Williams, Interim Director of Nursing Assuring Committee: Gold Command COVID-19 Date last reviewed: 24th May 2021					
Controls (What are we currently doing about the risk?)	Mitigating actions (What more sho	uld we do?)				
Alternative decontamination options being worked through for some items to	Action	Lead	Deadline			
enable re-use. Military assistance in place in Morriston from 20/04/20 to support improvement in logistics operation	Strengthened central distribution of PPE in place with electronic feed of supply requirements from individual units. Stock levels monitoring via dashboard. Pursue of local supply options underway for PPE with large supply anticipated in 01/05/20 and further quantities on order.	Director of Nursing	Weekly ongoing			
Assurances	Gaps in assurance					
(How do we know if the things we are doing are having an impact?)	(What additional assurances should we seek?)					
Executive monitoring/support to achieve improvement plans on a weekly basis. Current Risk Rating	The need to deliver sustained service. Additional Comments					
Initial Risk 25 Current 12 Target 10	Alternative decontamination options being worked through for Military assistance in place in Morriston from 20/04/20 to sup operation. 12.05.20 - Supplies have increased with regular r 24hrs in unit stores, most PPE items 48hrs plus, with a furth Confirmation of current and new suppliers providing steady a Discussion at Gold 28.08.20: No alteration to post-MA risk s ongoing re 9332+ and 8833 masks given that the flight conta 09.08.20, as expected. All-Wales PPE Executive meeting to alternative masks on order. Reconsideration of score to occ Discussion at Gold 18.09.20 & 22.10.20: No alteration to po Discussion at Gold 29.10.20 & 06.11.20: No alteration to post Discussion at Gold 30.11.20: No alteration to post-MA risk s Discussion at Gold 30.11.20: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 07.01.21: No alteration to post-MA risk s Discussion at Gold 24.1.21: No alteration to post-MA risk sc Discussion at Gold 24.1.21: No alteration to post-MA risk sc Discussion at Gold 12.2.21: No alteration to post-MA risk sc Discussion at Gold 12.2.21: No alteration to post-MA risk sc	or some items to e pport improvement eporting from unit er 48hrs held in H supply of PPE to t core required curre aining supplies did be held next week ur next week. st-MA risk score r st-MA risk score r st-MA risk score r core required curre core required curre core required curre core required curre to re required curre state to a state to a core required curre to a state to a state to a core required curre to a state to a state to a core required curre to a state to a state to a core required curre to a state to a state to a core required curre to a state to a state to a core required curre to a state to a state to a core required curre to a state to a state to a core required curre	nt in logistics ts of a minimum of IQ central store. the Health Board. rently. Issues dn't arrive on ek. Hoods and required currently. required currently. rently.			

Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently and for
further discussion at Nosocomial Group.
Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently.
25.02.21: The national picture for PPE is in a positive position with regular updates distributed
through the all Wales Exec PPE group. Local supplies of PPE are in excess of 12 days, with
FFP3 currently over 75 days. Regular reporting through to CCC and Gold continues to provide
assurance on the PPE position.
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 15.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Good
supplies available.
Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. however,
MP to consider review of narrative.
Discussion at Gold 20.04.21: Risk score reduced in line with updated litigations. Score reduced
to 12 from 15
Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. Agreed to
retain FAO of Gold. This is COVID-related, organisation-wide risk. There is currently more than
sufficient PPE supply. There is national reluctance to ease restrictions, particularly in relation to
FFP3's, however, due to the ongoing potential for a 3rd COVID wave.
Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently. Agreed to
retain FAO of Gold. This is COVID-related, organisation-wide risk. There is currently more than
sufficient PPE supply. There is national reluctance to ease restrictions, particularly in relation to
FFP3's, however, due to the ongoing potential for a 3rd COVID wave.
Discussion at Gold 17.05.21: No alteration to post-MA risk score required currently. Agreed to
retain FAO of Gold. This is COVID-related, organisation-wide risk. There is currently more than
sufficient PPE supply. There is national reluctance to ease restrictions, particularly in relation to
FFP3's, however, due to the ongoing potential for a 3rd COVID wave and there is no change to
this risk. Agreed to retain the same today.
Discussion at Gold 24.05.21: No alteration to post-MA risk score required currently

Datix ID Number: 2369	R_COV_Strategic_004		
Risk: <u>Covid related sickness absence</u> Number of staff who are absent from work through self-isolation or family illness will impact on ability to deliver safe care for patients; and will impact on ability to keep capacity open and to staff surge and super surge capacity. NOTE This risk ONLY captures the total of staff absence as reported weekly to WG risk score reflects the position in comparison with wave one position which peaked at 1700 staff absent.	Director Lead: Kathryn Jones, Interim Director of Workforce Assuring Committee: Gold Command COVID-19 Date last reviewed: 24 th May 2021		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more should	we do?)	
Operational deployment group now operational to balance staff workforce	Action	Lead	Deadline
 Field hospital staffing model identified; and will be triggered on basis of move to super surge with deployment in line with agreed minimum staffing requirements detail of Mitigating action relating to Recruitment set out in Risk 009a. From early Sept Staff absent for covid reasons self-isolation/shielding or symptomatic started to increase after reducing to less than a third of the peak levels. Symptomatic absence has increased to levels last seen in early June 2020. Asymptomatic absence is fluctuating as there has been significant success in reviewing shielding staff and bringing them back into some role. This is balanced by an increase in asymptomatic absence due to self-isolation. Symptomatic absence has continued to increase but total absence has levelled off in the last three weeks. Fluctuation in numbers this week linked to social distancing issues with medical staff. 	Workforce silver is leading a recruitment drive to secure additional workforce; robust occupational health service in place to identify and test staff quickly and get them back to work;	Director of Workforce	Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis.	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.		
Current Risk Rating 5 x 1 = 5 Initial Risk 25 Current 5 Target 8	Additional Comments Staff absent for covid reasons self-isolation/shielding or symptomati a third of the peak levels. Workforce continue to review shielding st priority work that can be undertaken at home. Announcement on pa 16th August likely to see some shielding staff able to return in some Discussion at Gold 11.09.20: No alteration to post-MA risk score red Watching brief in place due to issues beginning to surface. Discussion at Gold 18.09.20: No alteration to post-MA risk score red place due to increase in numbers over last 10 days. 40 asymptomat included. Units seeing rise in staff self-isolating with children who ar	aff with a view to p aused shielding an capacity. quired currently. quired currently. W tic and 47 symptor	oossible use in d changes w/e atching brief in natic staff,

not currently causing operational issues. 22.10.20 - Symptomatic absence has increased to levels last seen in June 2020. Asymptomatic absence is fluctuating as there has been significant success in reviewing shielding staff and bringin them back into some role. This is balanced by an increase in asymptomatic absence due to self- isolation. Discussion at Gold 29.10.20: risk needs increasing significantly. Although staffing patterns are different than those seen in the first wave and we aren't near trigger points, there are more services running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 13.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 33.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 31.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 31.11.20: No alteration to post-MA risk score required currently.
 absence is fluctuating as there has been significant success in reviewing shielding staff and bringin them back into some role. This is balanced by an increase in asymptomatic absence due to self-isolation. Discussion at Gold 29.10.20: risk needs increasing significantly. Although staffing patterns are different than those seen in the first wave and we aren't near trigger points, there are more services running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
 them back into some role. This is balanced by an increase in asymptomatic absence due to self-isolation. Discussion at Gold 29.10.20: risk needs increasing significantly. Although staffing patterns are different than those seen in the first wave and we aren't near trigger points, there are more services running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
 isolation. Discussion at Gold 29.10.20: risk needs increasing significantly. Although staffing patterns are different than those seen in the first wave and we aren't near trigger points, there are more services running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 29.10.20: risk needs increasing significantly. Although staffing patterns are different than those seen in the first wave and we aren't near trigger points, there are more services running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
different than those seen in the first wave and we aren't near trigger points, there are more services running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
running. This should be reflected as a significantly higher risk as is being reported to WG, particular in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
in relation to TTP and vaccination. Julian Rhys Quirk progressing plans to escalate the risk, update next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
next Gold command meeting. Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 06.11.20: JRQ revised risk as discussed last week. In light of ongoing discussio re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
re workforce, however, the wording may need reframing to capture new themes arising. Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 13.11.20: JRQ has reviewed this risk which relates to total number of staff. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 30.11.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.
Discussion at Gold 07.01.21: From early Sept Staff absent for covid reasons self-isolation/shielding
symptomatic started to increase after reducing to less than a third of the peak levels. Symptomatic
absence has increased to levels last seen in early May 2020. Following a period of accelerated
increase in numbers pre Xmas there has been a significant reduction in covid absence over and
immediately after the Xmas period. The announcement on shielding has not led to a marked incre
in asymptomatic numbers with the possible exception of medical staff at Morriston. Covid absence
decreased to 650 the same level as early December. Risk score not adjusted but if reductions
continue the score will be reviewed.
Covid absence decreased to below 500 the same level as early November Risk score reduced in l
with lower Covid Absence. Asymptomatic absence lowest level since peak of Wave 1.
Discussion at Gold 24.01.21: This has been reduced to red 20 due to staff returning. JRQ to revise
again, as required.
Discussion at Gold 01.02.21: This has been reduced to amber 15 to reflect a reduction in the numb
of COVID-related staff absences to below 350. This puts the risk score in line with that at the point
when staffing was last at this level.
Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. A watching brid
will be required here in light of reports of 2nd dose vaccines causing flu-like symptoms and driving a
subsequent increase in staff absence.
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. KJ to review by
08.03.21
Discussion at Gold 08.03.21- This had been reviewed and reduced in line with changes to COVID-

related sickness absence.
Discussion at Gold 15.03.21- This had been reviewed and reduced in line with changes to COVID-
related sickness absence. Risk has been reviewed this week and is as low as it is likely to go for the
foreseeable future. – It has Reduced from Amber 15 to Yellow 5.
Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently.
Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently.
Formal shielding ended 31st March 2021 which has had some impact on staff absence. Covid
absence continues to decrease and is now below 175 the lowest level since wave 1 peak. Risk score
reduced in line with lower Covid Absence, which continues to reduce at a slower rate.
Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently.
Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently: Agreed to retain
FAO of Gold.
Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently: Agreed to retain
FAO of Gold and to be reviewed by Workforce and OD this week.
Discussion at Gold 17.05.21: No alteration to post-MA risk score required currently: Agreed to retain
FAO of Gold and to be retained – no change
Discussion at Gold 24.05.21: No alteration to post-MA risk score required currently: Agreed to retain
FAO of Gold and to be retained – no change

Datix ID Number: 2370	R_COV_Strategic_005		
Risk: <u>Care Homes</u>	Director Lead: Brian Owens, Director of Primary and Communi	ity Services	
Potential failure in local care home sector to manage staff absences could result in	Assuring Committee: Gold Command COVID-19	,	
emergency closure of care home which will place undue pressure and therefore on	Date last reviewed: 24th May 2021		
community health and social services to support and/or lead to an increase in patient	······································		
admission to hospital. Risk of patient harm if care homes are not adequately covered.			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more shoul	ld we do?)	
HB has provided temporary support to one care home and working closely	Action	Lead	Deadline
with social services. Emergency care home procedure in place enacted via	Further plan required from Community Silver on alternative	Director of	Weekly
CSSIW.	models - e.g. step up care.	Primary and	ongoing
 Escalated to WG on 16/04/20 with strong view from WG that HB should not 		Community	
÷		Services	
•			
•			
Since April 2020 the Unit has:			
 Increased our monitoring of care homes; 			
 Established weekly reporting of care homes; 			
 Manage our hotspots with our partners; 			
 Testing of residents and staff has been completed and pathways to testing 			
•			
•			
Assurances			
• • • • • • •	The need to deliver sustained service.		
			liver. Also,
		011 25 10 20.	
· · · ·	· ·	and alagaly	
		fred closely.	
	•		
· · · ·	ion within care nomes is increasingly vulnerable.		
	D COMMAND - Last undated 21 June 20217	uno 2021	
 Established weekly reporting of care homes; Manage our hotspots with our partners; Testing of residents and staff has been completed and pathways to testing remain in place. When needed we have stepped in and physically supported the homes. The risk is being mitigated and has reduced from 25 to 20. Assurances (How do we know if the things we are doing are having an impact?) Executive monitoring/support to achieve improvement plans on a weekly basis. 	rt term support which has enabled the risk score to be reduced fro eral risk in sector re capacity. asing concern re cases in sector, however, which are to be monito rently. rently. ion within care homes is increasingly vulnerable.	Services kly to Community Si om 25 to 20. ored closely.	ilver. Also,

Э r

Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Sector remains fragile - weekly regional escalation process established via community silver. Support team established between both LA's and the HB to cover the period over Christmas and throughout Jan 2021 should a home setting require intensive intervention and support. Throughout the current period multiple home's requiring support from LA's and HB. Discussion at Gold Command 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. BO to advise of any required change following discussion by Community Silver Group which has the full picture for consideration. Discussion at Gold Command 15.02.21: No alteration to post-MA risk score required currently. CW stated that there is still a risk in this area, despite improvements seen. This is to be monitored with a view to reducing the risk in the near future. Discussion at Gold Command 22.02.21: In light of the reduction of the community care home risk to 3(12), this is to be reviewed down to an amber 12 outcome. BO. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently.BO is happy with this and no further review is required currently. Discussion at Gold 08.03.21- For review at Community Silver on 09.03.21. Discussion at Gold 15.03.21- No alteration to post-MA risk score required currently. Community Silver meetings are considering care homes on a fortnightly cycle, thus, this is to remain as it stands until next review by the group. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. Risk is reviewed every Tuesday at Community Silver and reflects current position. Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. AM to request that Tanya Springs reviews the risk, with a view to downgrading, at Community Silver Group. Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently. For regular review at Community Silver Group on 20.04.21. Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. Possibility that this could be picked up outside of Gold, however, this is to be monitored with a view to transitioning the risk. Consideration required of whether COVID remains the main risk to care homes. This is less likely the case in the current environment with more issues identified relating to sustainability and occupancy. Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently: Agreed to retain FAO of Gold. Discussion at Gold 17.05.21: No alteration to post-MA risk score required currently: Discussion at Gold 24.05.21: No alteration to post-MA risk score required currently: Agreed to retain FAO of Gold and to be retained - no change **Current Risk Rating** $4 \times 3 = 12$ 25 **Initial Risk** 12 Current 15 Target

Datix ID Number: 2371	R_COV_Strategic_006		
Risk: <u>Equipment Shortages</u> Inability to secure adequate supply of equipment to support phases of capacity plan which may restrict ability of Board to respond to peaks in pandemic if not mitigated. This includes availability of ventilators, CPAP, suppliers, syringe drivers	Director Lead: Darren Griffiths, Interim Director of Fin Assuring Committee: Gold Command COVID-19 Date last reviewed: 30 th November 2020	ance	
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)	
Detailed equipment schedule prepared.	Action	Lead	Deadline
CLOSED	Infrastructure Silver reviewing equipment provision to ensure that all requests are being pursued via national and local supply chains. For update on 23/04/20	Head of Capital Finance	Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis.	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.		
Current Risk Rating	Additional Commen	ts	
$5 \times 2 = 10$	Ventilators to come through critical care network - all o		dered or in
Initial Risk 25 Current 10			
Target 5	Risk likelihood reduced to reflect progress made. Update 27.07.20 - based on revised modelling figures from WG (24.06.20) the equippin group has now covered all capacity requirements. This risk to be closed and re-opened modelling requirements change adversely from current plans.		

Datix ID Number: 2372	R_COV_Strategic_007		
Risk: <u>Oxygen Provision</u> Capacity constraints on oxygen provision at Morriston will limit number of ventilator, CPAP and high flow oxygen beds. Lack of ability to secure direct suppliers via BOC will hamper plans for oxygen provision within field hospital	Director Lead: Darren Griffiths, Director of Finance Assuring Committee: Gold Command COVID-19 Date last reviewed: 30 th November 2020		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)	
Detailed risk assessment completed and mitigating actions in place to balance the	Action	Lead	Deadline
 oxygen usage across Morriston across the 2 VIE systems. Alternative source of supply being sourced to provide oxygen at field hospital. 	Further request submitted to WG to support prioritisation of Morriston for upgrade in flow rates at one VIE at Morriston to boost oxygen flow rate.	Head of Capital Finance	Weekly ongoing
CLOSED			
Assurances (How do we know if the things we are doing are having an impact?)	Gaps in assurance (What additional assurances should we seek?)		
 Executive monitoring/support to achieve improvement plans on a weekly basis. 	The need to deliver sustained service.		
Current Risk Rating	Additional Comments		
5 x 2 = 10	BOC solution agreed for Llandarcy - risk reduced to re	flect this. Risk will re	educe further
Initial Risk 25	when in situ.		
Current 10	19.06.20: Concrete base complete for Oxygen facility a		
Target 3	construction. BOC due to attend site end of week com piping to complete installation week commencing 29th		
	Recently closed but being monitored in relation to prov		al.

Datix ID Number: 2373	R_COV_Strategic_008					
Risk: <u>Capacity</u> Capacity requirements against national modelling mean that the HB capacity may be either insufficient to cope with demand of 2nd surge, resulting in an inability to care for patients as well as an increased risk of excess death.	Director Lead: Rab McEwan, Chief Operating Officer Assuring Committee: Gold Command COVID-19 Date last reviewed: 10 th May 2021					
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)				
 Capacity plans in place as described in Q3/Q4 plan. However, review of plans has been undertaken and agreement to bring additional areas into use - e.g. Tawe. Ward 7 currently also in use but will need to be decommissioned to enable cladding work at Singleton to progress. Additional information built into dashboard to enable oversight of core and sure capacity including capacity that may not be in use. Agreement that all surge must be in use before triggering field hospital provision 	Action Create flexible capacity plans that can be stepped up or down depending on demand and in line with other factors such as workforce, or medicines constraints Transferred to Operational Silver Group Risk Log	Lead Chief Operating Officer	Deadline Weekly ongoing			
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis. Gaps in assurances should we seek?) The need to deliver sustained service.						
Executive monitoring/support to achieve improvement plans on a weekly basis. The need to deliver sustained service. Additional Comments Reduce to 16 due to localised planning and modelling. 31.07.20. Localised planning and modelling in place allowing sufficient mitigation for the reduction of the risk score. Discussion at Gold 21.08.20: No alteration to post-MA risk score required currently. Ongoing updates to modelling work provide reassurance. Discussion at Gold 11.09.20: No alteration to post-MA risk score required currently. Requires ability to step up/down in line with competing demands. Discussion at Gold 11.09.20: No alteration to post-MA risk score required currently. Scope to review post-completion of capacity and Q3&4 planning. Discussion at Gold 18.09.20, 22.10.20 & 29.10.20: No alteration to post-MA risk score required currently. Discussion at Gold 6.11.20: No alteration to post-MA risk score required currently. Consideration will shortly be needed in light of pressures, however, of need to escalate to a score of 20. Discussion at Gold 31.11.20: Risk score to 25 due to the position being perilously close to capacity in terms of staff and beds out of use. DE to discuss with JRQ whether the score of this risk and those of risks 9a and b need to be made consistent. Discussion at Gold 30.11.20: Physical bed capacity available but the staffing resource is not available to open these beds. Risk increased given the workforce challenges. Operational silver working to mitigate the risk. Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 07.01.21: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.21: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.21: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.22. No alteration to post-MA risk score required currently. Disc						

Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.

Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. For review. HE to consider possibility of merging Risk ID008 and Risk ID010.

01.03.21: CW and HE to consider scope to de-escalate, however, pressures in system relating to the need to maintain IPC measures and COVID capacity are to be borne in mind. Discussion at Gold: 08.03.2021: For review at Operational Silver Group.

Discussion at Gold: 15.03.2021: Reviewed at Operational Silver with updates to mitigations included. - The Score has been Reduced from 25 to 20.

Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently.

RM is to be noted as risk owner and review in light of him taking over the COO role. Some surge capacity is still in use. This will be discussed at Operational Silver Group.

Discussion at Gold 29.03.2021: For review at Operational Silver Group. Score seems appropriate due to uncertainty, however.

Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. Under review by RM. Risk reduced to 10

Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently.

Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. To be picked up at Operational Silver Group.

Capacity plans in place. Under active review through operational sliver recovery group. Additional information built into dashboard to enable oversight of core and surge capacity and recovery including capacity that may not be in use. Field hospital provision available. The health board has used the WG 'most likely scenario' for modelling capacity and demand assumptions re 3rd wave to set levels of planned activity. Transferred to Operational Silver

Discussion at Gold 10.05.2021: CLOSED and transferred to Operational Silver Group risk log.

Current Risk Rating 5 x 2 = 10

Initial Risk	25
Current	10
Target	8

Datix ID Number: 2374	R_COV_Strategic_009a		
Risk: <u>Workforce Shortages</u> Measures the risk to service provision, deployment plans and HB strategic workforce related developments i.e. surge capacity, field hospital / Imms programme in the context of the number of available staff. Factors impacting cover Covid and general sick absence, deployment restrictions relating to staff covid risk assessment, general turnover, Outbreaks. Key risk areas where specific workforce shortages impact is the greatest e.g. ITU, A&E, Covid wards are reflected in the overall score.	Director Lead: Kathryn Jones, Interim Director of V Assuring Committee: Gold Command COVID-19 Date last reviewed: 24 th May 2021	Vorkforce	
Controls (What are we currently doing about the risk?)	Mitigating actions (What more	should we do?)	
 Rolling programme of recruitment to Registered Nurse and HCSW bank staff and Bank A&C. TTP risk captured elsewhere. All bank only staff have been approached with an option to move to a FT contract. Service groups are undertaking their own recruitment to substantive roles. Overall the pool of potential recruits is being accessed as much as is possible. Training capacity has been increased for HCSW Induction to maximum levels, some issues remain with MH training which are being addressed. Corporate Recruitment drive to secure additional workforce across substantive, bank and agency underway externally and internally. Robust occupational health service increased and in place to support staff in terms of general wellbeing. OH supporting internal Track and Trace. Service groups managing their own substantive recruitment to vacancies. Additional recruitment continues to be undertaken as required. Rolling programme of recruitment to Registered Nurse and HCSW bank staff and Bank A&C. TTP risk captured elsewhere. All bank only staff have been approached with an option to move to a FT contract. Overall the pool of potential recruits is being accessed as much as is possible. Training capacity has been significantly increased for HCSW Induction and MH. Deployment plans to assess whether staff can be used more effectively being organised corporately under Operational Management. Workforce data cell to support decision making established which incorporates data gathering (new data) exploiting existing data 	Additional workforce are being recruited through national and local campaigns including the return of retired NHS professionals	Lead Interim Director Workforce	Deadline Weekly ongoing
sources and roster efficiency. Risk score increased to mirror risk score 9b Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis. Additional Comm	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.		
Both Medical and Nursing student now deployed within the HB. Plans for recruitment and deployment undertaken as required. Issues remain with drop-out rates and staff returning to pre Covid roles affected TTP deployment. D requirements have been reduced by 50% for the time being easing the concerns over recruitment in t	under regular review to meet service planning as it e ue to low activity the TTP workforce requirements on	an all Wales basis	

Discussion at Gold 21.08.20: No alteration to post-MA risk score required currently. Future consideration required for possible revision upwards.

Discussion at Gold 04.09.20: No alteration to post-MA risk score required currently.

Discussion at Gold 11.09.20: No alteration to post-MA risk score required currently. Monitoring pressures on TTP and testing workforce. Possible need for review next week.

Discussion at Gold 18.09.20: No alteration to post-MA risk score required currently. Concerns ongoing; resolution dependent on success of ongoing recruitment.

Discussion at Gold 22.10.20: No alteration to post-MA risk score required currently

Discussion at Gold 29.10.20: This has been reviewed in the last week. Additional workforce has been recruited through local campaigns. Additional recruitment continues to be undertaken as required.

Discussion at Gold 06.11.20: The workforce staff supply risk has been assessed against the existing HB plan which had already highlighted the HB difficulties with staffing super surge. Risk has been increased due in part to evidence that the existing staffing and recruitment plan is being double counted as available resource. Whilst recruitment is ongoing and staff absence has NOT returned to previous levels seen (when matched to current Covid positive patients in the Hospital) concern has increased that reassurance is being incorrectly drawn from current plans. Whilst the pressure to staff the Immunisation programme has helpfully slipped into 2021, the supply of employed registered nurses is fixed. Agency options are being explored.

Discussion at Gold 13.11.20: Reviewed this week by JRQ. Relates to workforce requirements.

Discussion at Gold 23.11.20: DE to discuss with JRQ whether the score of this risk and those of risks 9a and b need to be made consistent. Await instructions.

Discussion at Gold 30.11.20: Physical bed capacity available but the staffing resource is not available to open these beds. Risk increased given the workforce challenges. Operational silver working to mitigate the risk.

Discussion at Gold 11.12.20 - Risk score increased to mirror risk score 9b

Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.

Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently.

Discussion at Gold 24.1.21: JRQ to review this ensuring that it matches Risk ID 004.

Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently.

Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. KJ to review by 15.02.21.

Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.

Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. KJ to review by 01.03.21.

Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. KJ to reduce this score.

Discussion at Gold:08.03.2021: Reviewed this week. No further alteration to post-MA risk score required currently.

Discussion at Gold:15.03.2021: Risk has been reviewed this week and is as low as it is likely to go for the foreseeable future. Reduced from 25 to 10.

Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently.

Scores correspond to other, related risks noted.

Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently.

Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. KJ to review.

Discussion at Gold 20.04.21: Risk Update No alteration to post-MA risk score required currently.

Discussion at Gold 26.04.21: Agreed to retain FAO of Gold. No alteration to post-MA risk score required given current steady state.

Discussion at Gold 10.05.21: Risk Update No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. To review by Workforce and OD this week

Discussion at Gold 17.05.21: Risk Update No alteration to post-MA risk score required currently.

Discussion at Gold 24.05.21: No alteration to post-MA risk score required currently: Agreed to retain FAO of Gold and to be retained – no change

		Current Risk Rating 5 x 2 = 10	
Initial Risk	25	5	
Current	10		
Target	10		
		CPUL Legith Deard COV/ID 10 Dick Degister COUD COMMAND Legt updated 21 June 20217 June 2021	

Datix ID Number: 2534	R_COV_Strategic_009b				
Risk: <u>Workforce Recruitment</u> Despite efforts to recruit staff into substantive, agency, bank and other roles the HB fails to meet the expanding requirement to replace staff covid related or increase staff resource as a consequence of new staff resource needs. The workforce staff recruitment/supply risk has been assessment NOT just against the existing HB plans which had already highlighted the HB difficulties with staffing super surge. The risk score reflects the risks with meeting every and all existing confirmed requirement. The risk includes the internal risk given the pressures on relatively small departments who need to support recruitment. There is significant pressure on the pool of Non registered staff in the SW of Wales with HBs and LA all recruiting from the same pool, this impacts not only on the availability but quality of candidates.	Director Lead: Kathryn Jones, Interim Director of V Assuring Committee: Gold Command COVID-19 Date last reviewed: 10 th May 2021	Vorkforce			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more	should we do?)			
NWSSP capacity to support the mechanics has been increased but in the context of a	Action	Lead	Deadline		
 Invocor capacity to support the incontaines has been increased but in the context of a significant increase in recruitment across Hywel Dda and SBU we have augmented support through using internal source to complete statutory checks. Bank have taken on a significantly expanded role running rolling recruitment for registered staff, HCSW and A&C. Interviews supported by staff from SGs. Other staff groups also need support but bank capacity itself has been exhausted. Bank have increased cover during the week and weekends, have deployed staff on site to support managers. Block booking of agency staff has been used when needed and we have and are continuing to explore off contract agency staff. SGs have been encouraged to accelerate their part in recruiting to substantive vacancies. Both TTP and Imms programme have groups just addressing recruitment. For A&C staff we are using the HB vocational training cell to identify staff from their programme complete training and PEC checks and liaise with local job centres to secure IT literate candidates for Imms booking centre staff and supervisors/managers. Every option to reduce workload and the back office administration linked to recruitment has been taken whilst ensuring the minimum required checks are in place. Improved attendance linked to reduced covid related absence impacting on fill rates and recruitment requirement remains at RED but 20. 	Additional workforce are being recruited through national and local campaigns including the return of retired NHS professionals	Assistant Director Workforce	Weekly ongoing		
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis.	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.				
Additional Comm Risk added after Gold meeting 13.11.20. Addition made by JRQ this week. Score is high because we		clarified that there	is an issue is		
	SBU Health Board COVID-19 Risk Register – GOLD COMMAND – Last updated 21 June 20217 June 2021				

with testing and that some candidates are saying that a contract up until the end of March is too short. JRQ to pick this up with SV. Discussion at Gold 23.11.20: DE to discuss with JRQ whether the score of this risk and those of risks 9a and b need to be made consistent. Await instructions Discussion at Gold 30.11.20: Physical bed capacity available but the staffing resource is not available to open these beds. Risk increased given the workforce challenges. Operational silver working to mitigate the risk. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. The score reflects the position of staff returning, however, recruitment is still critical. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. The score reflects the remaining potential for issues with recruitment. Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. KJ to review by 15.02.21 Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. KJ to review by 01.03.21. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. KJ to review by 08.03.21. Discussion at Gold:08.03.2021: Reviewed this week. No further alteration to post-MA risk score required currently. Discussion at Gold:15.03.2021: Risk has been reviewed this week and is as low as it is likely to go for the foreseeable future. Reduced from 25 to 8. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Scores correspond to other, related risks noted. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. KJ to review. Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently. JRQ to check whether risk score can be reduced. Reduced to 4. Discussion at Gold 26.04.21: Agreed to retain FAO of Gold. No alteration to post-MA risk score required currently. Still recruiting, in part – risk to remain open. Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently. : Agreed to close. **Current Risk Rating** $4 \times 1 = 4$ Initial Risk 25 4 Current 10 Target

Datix ID Number: 2375	R_COV_Strategic_010		
Risk: Delivery of Essential Care Following the guidance to step down routine activity issued by Welsh Government and the pandemic Health and Social Care Response Plan, hte R&R programme was overseeing the restart of routine and essential services. Some services remain significantly under pre-covid capacity. There is a risk that the delivery of essential and routine services will be disrupted again through a 2nd peak in COVID admissions and levels of service delivery will need to be adjusted to support the covid response.	Director Lead: Rab McEwan, Chief Operating Officer Assuring Committee: Gold Command COVID-19 Date last reviewed: 10 th May 20 21		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)	
Urgent OP work will continue utilising digital solutions wherever possible.	Action	Lead	Deadline
 Agreed list of exceptions in place; urgent cancer work is being preserved as far as 	Development of recovery framework to support	Chief Operating	Weekly
practicable given other constraints.	return to delivery of core services	Officer	ongoing
Use of Sancta to provide some urgent cancer treatment.			
• Discussions on regional footprint to identify potential solutions for urgent work where	Transferred to Operational Silver Group Risk Log		
 appropriate. Morriston remains open to the Burns network. 			
 Proposal to use "reverse" QIA tool to risk assess service that may need to be adjusted to support covid demand. A system wide approach to be managed through operational 			
silver. Ambition is to retain more services than surging first phase but Workforce and			
capacity availability however will determine levels. LHB will continue to engage in			
regional and national work to develop solutions for "covid free" (AG letter 20 Oct).			
Workforce and capacity availability however will determine levels.			
• From May through summer service were methodically restarted using a QIA approach.			
Since Sept 20-20 agreement for no new service to be restarted due to rising covid			
demand. Through the managed retreat process and in line with WG Local Choices f/w			
face to face outpatients were stopped for all but urgent cases and orthopaedic operating			
in NPT. Choices framework under constant review. Self-assessment against essential			
services being redone in Jan 21.			
• Capacity plans for 2021-22 are in place. These are under active review through			
operational sliver recovery group which will provide assurance on ongoing delivery of			
essential services and restart of the elective programme. Additional information built			
into dashboard to enable oversight of core and surge capacity and recovery including			
capacity that may not be in use. Field hospital provision available. The health board			
has used the WG 'most likely scenario' for modelling capacity and demand assumptions			

re 3rd wave to set levels of planned activity. The Health board will maintain a Gold				
response capability through the period, and operational Silver Group will respond to				
escalation levels, stepping up or down the relevant services.				
	Como in accurrence			
Assurances	Gaps in assurance			
(How do we know if the things we are doing are having an impact?)	(What additional assurances should we seek?)			
Executive monitoring/support to achieve improvement plans on a weekly basis.	The need to deliver sustained service.			
Additional Co				
Update as at 21.08.20: No alteration to post-MA risk score required currently, however, effects of it	numerous guidelines published to be monitored, as well as t	the effect of some staff being		
able returning to work.				
Discussion at Gold 11.09.20: No alteration to post-MA risk score required currently.				
Discussion at Gold 18.09.20: No alteration to post-MA risk score required currently. Increase in nu				
An essential services assurance tool has been developed by Welsh Government, and through the				
escalation framework has been developed and will be tested to ensure that the HB makes decision	ns taking into account the potential direct and indirect harm	from COVID. (To be updated		
after prioritisation discussion on 28/09/20)				
Discussion at Gold 22.10.20 - No alteration to post-MA risk score required currently.				
Discussion at Gold 29.10.20: No alteration to post-MA risk score required currently. To be reviewed	ed and reinforced as appropriate.			
Discussion at Gold 06.11.20: No alteration to post-MA risk score required currently.				
Discussion at Gold 13.11.20: No alteration to post-MA risk score required currently.				
Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently, although, cons	sideration of increasing score may be needed soon depende	ent on how the situation		
progresses with electives.				
Discussion at Gold 30.11.20: Discussion around delivery of essential care. How can we step back	from the delivery of core services to mitigate the risk?			
Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.				
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.				
Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently.				
Discussion at Gold 24.1.21: No alteration to post-MA fisk score required currently. Discussion at Gold 24.1.21: Baseline assessment update is underway and capacity is still reduced. This will be reviewed again on completion of the update.				
Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Consideration of		tweek's scoring in line with work		
currently underway.		t week's scoring in line with work		
Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. For considera	tion in terms of revised Eccential Services Receipe Access	mont		
Discussion at Gold 05.02.21: No alteration to post-MA risk score required currently. For consideration to post-MA risk score required currently. CW stated the				
	at opportunities for resumption of services continue to be co	onsidered at Operational Silver		
Group. Orthopaedic surgery is to be resumed on 22.02.21.	E to consider possibility of mersing Disk ID000 and Disk ID	010		
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. For review. HE to consider possibility of merging Risk ID008 and Risk ID010.				
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. For review at	Operational Silver Group.			
Discussion at Gold:08.03.2021: For review at Operational Silver Group.	to be been desired. Note the set of the set of the set			
Discussion at Gold:15.03.2021: Reviewed at Operational Silver Group on the 9th March- narrative	· ·			
SBU Health Board COVID-19 Risk Register – GOLD CO	DMMAND – Last updated <u>21 June 20217 Jur</u>	ne 2021		

Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. RM is to be noted as risk owner and review in light of him taking over the COO role. This will be discussed at Operational Silver Group. Discussion at Gold 29.03.21: For review at Operational Silver Group. Difficult to reduce score as essential services are running a continuing backlog. Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. RM to review Discussion at Gold 20.04.21: Reduced to 10 Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. To be picked up at Operational Silver Group. Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently The Health board will maintain a Gold response capability through the period, and operational Silver Group will respond to escalation levels, stepping up or down the relevant services. Transferred to Operational Silver. Current Risk Rating

		5 x 2 = 10	
Initial Risk	25		
Current	10		
Target	8		

Datix ID Number: 2376	R_COV_Strategic_011		
Risk: Workforce Risk Assessment Tool There is growing evidence that COVID-19 is having a disproportionate impact on individuals from BAME backgrounds. A national risk assessment tool has been developed to support the Board in managing risks including for staff who have been in a shielded category. There is also a further risk that if shielding is reintroduced in Wales that this will exacerbate staffing difficulties in critical services There is a risk that staff members will not feel comfortable or safe in returning to the workplace			
which will have a negative impact on staffing levels.			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s		
 A risk assessment tool has been made available by Welsh Government to support the identification of health care workers who are at risk and to support the a risk assessment is to identify those individuals who may fit into this additional vulnerable group in order to prevent insofar as is possible, a worsening of the existing racial disparities in our communities. This tool was adapted and utilised for staff who have returned from shielding. BAME individuals will need to have a discussion with their line managers and a risk assessment undertaken on an individual basis giving due recognition to their profession or role in the organisation and their likely risk of current exposure to COVID-19. It is recognised that it is not possible to assess for all possible risk factors in this current environment. Factors such as genetics, socioeconomic factors, geographical and above all cultural factors will have an effect on risk – however they cannot be assessed here in this context and will need to form part of the risk assessment tool. CUOSEED 	Action The impact on services will be reassessed after the initial risk assessment process has concluded.	Lead Director of Workforce	Deadline Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis.	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.		
Additional Co Discussion at Gold 28.08.20: No alteration to post-MA risk score required currently, however, watch assessment. Discussion at Gold 04.09.20: No alteration to post-MA risk score required currently. Potential to re- Discussion at Gold 11.09.20: No alteration to post-MA risk score required currently. Discussion at Gold 18.09.20: Dealt with issues arising with LNC. No significant reduction in shielding	hing brief in place in light of changes to method of imple view and reduce following discussion at next week's LNC	С.	

of the risk ought to be changed as it now has a more general application. Potential for all-Wales reinstating of shielding in light of increase in cases seen. KR pointed out that the shielding cohort could include different people who have developed eligibility going forward. This could affect mission-critical individuals with the biggest impact likely to be seen in areas which have already successfully returned shielders. JRQ to review score and title.

To date, a number of staff have successfully returned to the workplace. There is no current plan to return to a national shielding programme. 22.10.20 - No issues reported with the use of the risk tool for some time now - risk can be closed.

Current Risk Rating 5 x 2 = 10			
5 x 2 = 10			
Initial Risk	25		
Current	10		
Target	8		

Datix ID Number: 2377	R_COV_Strategic_012	
 Risk: Partnership Working There are growing tensions between the Health Board and some trade union partners within SBUHB particularly in response to the supply of PPE which has the potential to create unrest in the workforce and hamper an effective response to COVID-19. Controls (What are we currently doing about the risk?) Frequent meetings will continue to take place, supplemented by local discussions when required. Employees will be encouraged to raise concerns via existing mechanisms and directly to the Chief Executive. We will continue to utilise the daily briefings to be transparent about issues such as PPE to improve confidence in the supply and availability. Chief Executive and other Executive Directors will attend HB Partnership Forum on a regular basis. Partnership principles and ways of working will be emphasised as the most effective approach to secure progress. The Health Board will continue to develop an effective working relationship with all trade union partners and collectively via the agreed HB Partnership Forum. Frequent meetings will be encouraged to raise concerns via existing mechanisms and directly to the Chief Executive. We will continue to take place, supplemented by local discussions when required. Employees will be encouraged to raise concerns via existing mechanisms and directly to the Chief Executive. We will continue to utilise the daily briefings to be transparent about issues such as PPE to improve confidence in the supply and availability. Chief Executive. We will continue to utilise the daily briefings to be transparent about issues such as PPE to improve confidence in the supply and availability. Chief Executive approach to secure progress. Despite extensive discussions at PF staff side formally raised a number of issues in writing indicating they have not accepted the information provided. 	Director Lead: Kathryn Jones, Interim Director of Wa Assuring Committee: Gold Command COVID-19 Date last reviewed: 20 TH April 2021 <u>Mitigating actions (What more Action</u> The Health Board will continue to develop an effective working relationship with all trade union partners and collectively via the agreed HB Partnership Forum. <u>Moved to the Health Board Risk Register</u>	 Deadline Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?) • Executive monitoring/support to achieve improvement plans on a weekly basis.	Gaps in assurance (What additional assurances should we seek?) The need to deliver sustained service.	

Additional Comments

Partnership principles and ways of working will be emphasised as the most effective approach to secure progress.

Discussion at Gold 21.08.20: Effects of recent activity to be monitored and score revised if subsequent change noted.

Discussion at Gold 18.09.20 & 22.10.20: No alteration to post-MA risk score required currently.

Discussion at Gold 29.10.20: No alteration to post-MA risk score required currently. No other major issues but nervousness remains around reducing this.

Discussion at Gold 06.11.20: No alteration to post-MA risk score required currently.

Discussion at Gold 13.11.20: No alteration to post-MA risk score required currently.

Discussion at gold 23.11.20 & 30.11.20: No alteration to post-MA risk score required currently. To be kept under review.

Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.

Discussion at Gold 21.12.20 Formal review required with a view to increasing to red 25.

Discussion at Gold 7.1.21: Risk score increased to 25 after further escalation of issues particularly PPE and the change to Imms policy and second dose.

Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Risk score remains at 25 staff side still escalating issues particularly PPE and the change to Imms policy and second dose.

Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently.

Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently.

Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.

Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. This risk remains high following receipt of communications from TUs re annual leave carry-over.

Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. KJ to review by 08.03.21

Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently. Issues continue to be raised in this arena, hence the requirement to maintain a high score.

Discussion at Gold 15.03.21: No alteration to post-MA risk score required currently. Issues continue to be raised in this arena, hence the requirement to maintain a high score.

Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently.

Group discussed consistently high position of risk score leaving no room for further escalation should situations worsen. Noted that sufficiently robust mitigating actions required if the score is to remain this high. JRQ reluctant to support reduction of the score in light of recent difficulty in relations with TUs, who have been threatening instigating Ministerial action. JRQ to discuss this with KJ

Discussion at Gold 29.03.21: For review this week.

Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. KJ to review and see if downgrade to score of 20 is possible.

Discussion at Gold 20.04.21 JRQ noted that this risk should have been reduced to 20 and cannot be reduced any further currently due to a number of ongoing issues. Risk score reduced to reflect immediate impact only. Significant tensions remain. Access to all Wales support to help reduce concerns under consideration.

Discussion at Gold 26.04.21: Group agreed transfer to Corporate Risk Register for monitoring by the Workforce & OD Committee.

Current Risk Rating 4 x 5 = 20			
Initial Risk	25		
Current	20		
Initial Risk Current Target	8		

Datix ID Number: 2388	R_COV_Strategic_013			
Risk: <u>Test, Trace, Protect</u> The TTP programme is operational and staff have been recruited to both regional and local	Director Lead: Sian Harrop-Griffiths, Director of Strategy			
teams. There is a risk that there will be insufficient capacity locally to contend with significant or prolonger outbreaks and the sustainability of the service is a concern given the temporary nature of deploying people from core roles. There is also a risk that testing capacity may not be sufficient to deal with sudden upsurges in demand. Longer laboratory times will negatively impact on the effectiveness of contact tracing.				
CLOSED				
Controls (What are we currently doing about the risk?)	Mitigating actions (What more sh	ould we do?)		
Public Health Protection and Response Plan in place and submitted to WG. TTP teams	Action	Lead	Deadline	
are operational and decisions made to recruit staff into roles on a longer term basis to provide continuity. Additional support requested in light of upsurge of cases in	Need to establish clear position on retesting. Action completed	Director of Strategy	Weekly ongoing	
September and recruitment/deployment plans being reassessed. Discussion around release of additional clinical leads from Health Board.	TTP manage this risk within the TTP Cell			
• Review of testing capacity has taken place and additional slots created at both CTU's. Mobile Testing Units operational from 28th September. Additional walk in site scoped				
and will be operational during October. Additional Laboratory capacity has been confirmed through national TTP programme.				
Assurances (How do we know if the things we are doing are having an impact?)	Gaps in assurance (What additional assurances should we seek?)		I	
Executive monitoring/support to achieve improvement plans on a weekly basis.				
	Comments			
Discussion with WG planned over funding w/c 25.06.20 with potential for follow up letter - TBA Amber 15 - appropriate at the moment. Still significant uncertainty.	at Chairs/Leaders/CEOs Call on 02.07.20.			
Discussion at Gold 28.08.20: No alteration to post-MA risk score required currently, however, increasing concern re ability to scale-up TPP operations in light of increased cases seen in Cardiff.				
Discussion at Gold 04.09.20: No alteration to post-MA risk score required currently. Remains under review; situation currently stable. Discussion at Gold 11.09.20: No alteration to post-MA risk score required currently.				
Discussion at Gold 11.09.20. No alteration to post-tria fisk score required currently. Discussion at Gold 18.09.20: For review in light of national concerns. Locally, the system is strained but continues to operate.				
22.10.20 - Confirmed release of clinical leads within Health Board to support TTP. Capacity of TTP to deliver as required escalated nationally due to shortage of specialist health protection staff on a national level.				
Discussion at Gold 29.10.20: Director of Strategy is taking the risk to the TTP group for discussion and update on 10/11/20. This risk is likely to be higher than stated. Revision required. Discussion at Gold 06.11.20: SHG is taking this risk to the TTP group on 10.11.20 for review.				
Discussion at Gold 13.11.20: Recently reviewed. TTP Silver to consider again tomorrow.				
Discussion at Gold 23.11.20 & 30.11.20: Recently reviewed. TTP Silver to consider again today and report back on whether review required.				

Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.20: Position has increased to red in relation to SCG. Risk to be raised to red 20 provisionally ahead of formal confirmation following review by TTP Silver. Discussion at Gold 7.1.21: Risk increased to red. Testing capacity saturated, but plans in place to increase capacity - additional capacity coming on line w/c 4th January. Tracing teams unable to cope with demand - fully staffed to funded levels, maximising redeployment of staff from LAs where possible. Mutual aid/support from the national team requested on several occasions. Testing turnaround times poor, especially from Public Health Wales lab at Singleton. Meeting held on 23/12 and performance improvements expected w/c 28/12 and 4/1. Discussion at Gold 24.1.21: To be changed to Amber 15 in light of downgraded BRAG rating to 15. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Potential for comment at today's TTP Programme Board. Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Group to be advised of any review required following TTP Silver Group Meeting. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Group to be advised of any review required following TTP Silver Group meeting today. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Group to be advised of potential to downgrade the risk following TTP silver Group meeting today. Discussion at Gold 08.03.21: Reviewed this week and score to be retained as it stands, currently. Staffing remains a concern in this arena. Discussion at Gold 15.03.21: Silver Meeting today - TTP risk has been downgraded to green. This is to be considered for alignment. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Risk to remain open however as relates to ongoing issue. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently. Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. Risk to remain open given issues regarding duration of need and replacement. Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently. Risk to close and request TTP manage this risk within the TTP Cell Discussion at Gold 17.05.21: Risk Update No alteration to post-MA risk score required currently. Risk to close and requested TTP to manage this risk within the TTP Cell. They are not meeting until 24th May 2021, therefore awaiting confirmation. **Current Risk Rating** $4 \times 1 = 4$ **Intital Risk** 20

4

8

Current

Target

Datix ID Number: 2456	R_COV_Strategic_014 CLOSED
Risk: <u>Key worker support from schools</u> Both Swansea and NT Local Authorities have indicated they do not have plans to provide key worker support over the 6-week summer break. As some staff may not be able to access the support they would have normally have relied upon during this period due to Covid restriction, these staff may have no options but to remain at home to care for their children. Existing policy during the pandemic was that we did support staff in these circumstances by providing basic pay only.	Director Lead: Kathryn Jones, Interim Director of Workforce Assuring Committee: Gold Command COVID-19 Date last reviewed: 30 th November 2020
Controls (What are we currently doing about the risk?)	Mitigating actions (What more should we do?)
 Workforce considering how to assess the numbers of staff this may affect. Issue raised on all-Wales basis. LA offering to provide details of available child care and financial support available but it is yet unclear the scale of options available. The net effect would be an increase to the numbers of staff off work but asymptomatic. 	Action Lead Deadlin TBC Interim Director of Workforce Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?)	Gaps in assurance (What additional assurances should we seek?)
Current Risk Rating 1 x 3 = 3 Initial Risk 15 Current 3 Target 8	Additional Comments Discussion with WG planned over funding w/c 25.06.20 with potential for follow up lett TBA at Chairs/Leaders/CEOs Call on 02.07.20. HB policy issued 13th July 2020 providing local guidance on managing for those staff cannot find suitable child care options for the summer break. Initial estimates were numbers of staff affected were low. WG have confirmed that Schools will open fully Sept so we are assuming this issue will cease from that date although we will keep the situation under review to address any issues with pre-school childcare. Very low lev of reported issues - guidance and flexibility seems to have been used sensibly by staf and managers.

Datix ID Number: 2457	R_COV_Strategic_015a		
	Medium Term		
Risk: Mass Vaccination	Director Lead: Keith Reid, Director of Public Health		
The Health Board has operationalised its Mass Vaccination Programme in line with the	Assuring Committee: Gold Command COVID-19		
strategic plan submitted to WG in 2020. Risks that are being managed in the programme	Date last reviewed: 24th May 2021		
are:			
 Continuity of vaccine supply to enable the Board to meet the milestones set out in the National Vaccination Strategy for the first phase of the programme which is to vaccinate all JCVI groups 1-4 by mid-February Challenges in securing and retaining a skilled workforce to deliver the programme at scale and pace Deliver of a safe and effective programme that is being rolled out at pace and with significant and ensuring effective and timely communication to the public and key stakeholders 			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more sho	uld we do?)	
 A Silver immunisation cell has been mobilised and work cells identified to 	Action	Lead	Deadline
 establish detailed plans within known parameters. Influenza planning is proceeding at pace and this will be prioritised for early delivery in Sept/Oct ahead of COVID-19 vaccine. Exercise to test mass vaccination planning set up for 20th August and further risks will be quantified at this point. Initial plan presented to WG and feedback received. Presentation to National COVID Vaccination Board scheduled for 29th September. Critical path now in place and MVC sites scoping exercise nearing completion. Further information available on WIS, however note that the timescale remains tight for roll-out with little opportunity for local testing 	A detailed programme delivery plan is in place setting out the delivery mechanism, core assumptions, governance and ongoing management of risk. A detailed programme risk log has been developed and is being refined to reflect the operationalisation of the programme since December 2021. New governance arrangements are being established (in February) to streamline decision making arrangements.	Director of Public Health	Weekly ongoing
Assurances (How do we know if the things we are doing are having an impact?)	Gaps in assurance (What additional assurances should we seek?)		
Additional Discussion at Gold 28.08.20: Post-MA risk score is accurate for the moment. Considerable un Discussion at Gold 04.09.20: Post-MA risk score is accurate for the moment. Health Board Va Discussion at Gold 11.09.20: Post-MA risk score is accurate for the moment. Discussion at Gold 18.09.20: No alteration to post-MA risk score required currently. Silver Im dependencies for which clarity is awaited. Discussion at Gold 22.10.20 & 29.10.20: No alteration to post-MA risk score required currently. Discussion at Gold 06.11.20: No alteration to post-MA risk score required currently. This may Discussion at Gold 13.11.20: No alteration to post-MA risk score required currently. SBU Health Board COVID-19 Risk Register – GOLD	accination Plan submitted to WG on 03.09.20. New planning p munisation Group met yesterday and made progress, howeve ly. require review following the CVB table top exercise with milita- emed appropriate in light of contingencies in place.	arameters received r, there are a numb ary planners on 09.	er of critical

Discussion at Gold 30.11.20: Our preparation is not driving the risk score but the availability of the vaccine. Red 16 Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: DE to separate into 2 outlooks; short term and medium term. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. DE to review light of potential Pfizer supply issue. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 08.03.21: Reviewed this week. No further alteration to post-MA risk score required currently. There is still scope for things to go wrong but the Programme is currently OK. Discussion at Gold 15.03.21: Reviewed this week. Mass Vaccination- national supply issue- DE is to review as supply is more stable- The score has been reduced to Amber 15 from a Red 16. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Unable to reduce due to reduction in supply anticipated. Discussion at Gold 29.03.21: Possible reversal of scores of risks 15a and 15b to be considered in light of current position. Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. DE to review in light of ongoing changes to pattern of use of AstraZeneca. Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently. DE to revise narrative. Unlikely that a change to risk score will be required, currently, however. Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. DE to revise narrative. Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. DE has revised. Discussion at Gold 17.05.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. Discussion at Gold 24.05.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. **Current Risk Rating** $5 \times 3 = 15$ **Initial Risk** 20

15

10

Current

Target

Datix ID Number: 2457	R_COV_Strategic_015b		
	Short Term		
Risk: Mass Vaccination	Director Lead: Keith Reid, Director of Public Health		
The Health Board is developing its forward plan which will aim to vaccinate a greater	Assuring Committee: Gold Command COVID-19		
percentage of the population as part of the overall public health response. There are	Date last reviewed: 24th May 2021		
medium term risks around the allocation of sufficient vaccine to enable the programme to			
progress. In the medium term, there is an assumption that primary care will continue to			
be able to support the programme. Although many members of the workforce have			
been recruited on a fixed term basis, there are concerns about the stability of a core			
workforce. There is continued uncertainty about the policy direction and whether this will			
be adjusted by the Joint Committee on Vaccination and Immunisation and the nature of			
any proposed changes on the local programme. The public may not have faith in the			
local vaccine programme.			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more shou	ıld we do?)	
Programme delivery plan is in place and detailed demand and capacity tool	Action	Lead	Deadline
developed to inform local options assessment.	TBC	Director of	Weekly
 Mapping of 2nd dose requirements has been undertaken to inform WG of 		Public Health	ongoing
vaccine requirements. A weekly plan will be submitted to WG on 4th February			
as requested.			
Further options are being explored to enable a flexible delivery model including			
the establishment of Local Vaccination Centre.			
 Discussions are taking place with primary care to secure ongoing support to 			
utilise the PCCIS scheme to enable vaccine to be delivered closer to people's			
home.			
home.			
Assurances	Gaps in assurance		
(How do we know if the things we are doing are having an impact?)	(What additional assurances should we seek?)		
	onal Comments		
Discussion at Gold 24.1.21: DE to separate into 2 outlooks; short term and medium term.			
Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. DE to r	eview light of potential Pfizer supply issue.		
Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. DE to			
Discussion at Gold 08.03.21: Reviewed this week. No further alteration to post-MA risk sco			
Discussion at Gold 15.03.21: Reviewed this week. No further alteration to post-MA risk sco	re required currently. There is still scope for things to go wrong I	but the Programme	is currently OK
DE is reviewing.			
Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 29.03.21: Possible reversal of scores of risks 15a and 15b to be conside			
Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. D E to r	review in light of ongoing changes to pattern of use of AstraZene	ca.	
SBU Health Board COVID-19 Risk Register – GOL	_D COMMAND – Last updated 21 June 20217 J	une 2021	

		1.21: No alteration to post-MA risk score required currently. DE to revise narrative. Unlikely that a change to risk score will be required, currently, however. 1.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. DE to revise narrative.
Discussion at Go	ld 10.05	5.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold. DE has revised.
Discussion at Go	ld 17.05	5.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold.
Discussion at Go	ld 24.05	5.21: No alteration to post-MA risk score required currently. Agreed to retain FAO of Gold.
		Current Risk Rating
		4 x 3 = 12
Initial Risk	20	
Current	12	
Target	10	

Datix ID Number: 2491	R_COV_Strategic_016		
Risk: Bed Spacing	Director Lead: Rab McEwan, Chief Operating Officer		
Guidance was issued by WG in July setting out minimum requirements in respect of bed	Assuring Committee: Gold Command COVID-19		
spacing between hospital beds. As a result of a detailed risk assessment carried out at	Date last reviewed: 02 February 2021		
Board level, the Board will not be able to fully comply with this guidance in respect of a			
minimum 3.6m mid to mid bed, and 3.7m between from bed head to middle of space across			
to opposite bed. This increases the potential risk of nosocomial transmission. If beds are			
withdrawn from use due to non-compliance with the minimum standards, then this introduces	CLOSED		
risk around the loss of capacity and potential for patient harm to be caused across the			
system due to flow issues.			
Controls (What are we currently doing about the risk?)	Mitigating actions (What more sho	ould we do?)	
A detailed risk assessment has taken place and all inpatient areas have been reviewed	Action	Lead	Deadline
for compliance with the guidance. A Red /Amber/Green rating has been deployed	TBC	Chief Operating	Weekly
which means that Green = fully compliant; Amber - between 2m and 3.6m; Red =		Officer	ongoing
below 2metres. All Red bed areas have been removed. Mitigating action is being			
deployed and will be in place by end October.			
• Perspex curtain installation is on track; 90% completed as at 5/11/20 and should be			
fully completed by 09/11/20 including in the Bay Field Hospital. A number of residual			
areas where there is currently high infection levels will be part of a 'mop up' installation			
plan that will be completed in November.			
Assurances	Gaps in assurance		
(How do we know if the things we are doing are having an impact?)	(What additional assurances should we seek?).		
	Comments		
Discussion at Gold 29.10.20: Narrative to be updated to reflect delivery and installation of curta			
Discussion at Gold 06.11.20: No alteration to post-MA risk score required currently. Potential to	close this risk following completion of installation of perspe	curtains.	
Discussion at Gold 13.11.20: No alteration to post-MA risk score required currently.	.		
Discussion at Gold 23.11.20 & 30.11.20: No alteration to post-MA risk score required currently	Awaiting further guidance this week which may instigate ne	ed for review.	
Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently.			
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.	New with the first of the later of the later of the later of the first		
Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Moved in to		ol Outbreak meeting	gs.
Discussion at Gold 1.2.21: This risk can now be closed and will be subsumed by the No			
	lisk Rating		
	l = 12		
Initial Risk 16			
Current 12			
Target 9			

Datix ID Number: 2521	R_COV_Strategic_017		
Risk: Nosocomial transmission Director Lead: Richard Evans, Executive Medical Director Nosocomial transmission in hospitals could cause patient harm; increase staff absence and create wider system pressures (and potential for further harm) due to measures that will be required to control outbreaks. Director Lead: Richard Evans, Executive Medical Director Controls (What are we currently doing about the risk?) Date last reviewed: 24 th May 2021 Nosocomial transmission Silver established to report to Gold. A nosocomial framework has been developed to focus on: (a) prevention and (b) response. Mitigating actions (What more should we do? Preventative measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission, segregating positive, measures are in place including testing on admission segregating positive, measures are in place including testing on a	r		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more sh	ould we do?)	
 been developed to focus on: (a) prevention and (b) response. Preventative measures are in place including testing on admission, segregating positive, suspected and negative patients, reinforcing PPE requirements, and a focus on behaviours relating to physical distancing. As part of the response, measures have been enacted to oversee the management of outbreaks. Process established to review nosocomial deaths. Audit tools developed to support consistency checking in key areas re: PPE, physical distancing. Testing on admission dashboard in use. Further guidance on patient cohorting produced 	Nosocomial transmission Silver established to report to Gold. A nosocomial framework has been developed to focus on: (a) prevention and (b) response. Also added to Health Board Risk Register Gaps in assurance	Medical Director & Deputy	Deadline Weekly ongoing
required to control outbreaks. Controls (What are we currently doing about the risk?) Mitigating actions Nosocomial transmission Silver established to report to Gold. A nosocomial framework has been developed to focus on: (a) prevention and (b) response. Nosocomial transmission Silver established to report to Gold. A nosocomial framework has been of the prevention and (b) response. Preventative measures are in place including testing on admission, segregating positive, suspected and negative patients, reinforcing PPE requirements, and a focus on behaviours relating to physical distancing. As part of the response, measures have been enacted to oversee the management of outbreaks. Associate and the patients of outbreaks. Process established to review nosocomial deaths. Audit tools developed to support consistency checking in key areas re: PPE, physical distancing. Testing on admission dashboard in use. Further guidance on patient cohorting produced Also added to Health Board Risk Regis Assurances Caps in assurance What additional assurances should we for a doing are having an impact?) Caps in assurance Discussion at Gold 02.10.20 - risk added to register. Discussion at Gold 06.11.20: No alteration to post-MA risk score required currently. Reflects current concern re outbreaks. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. DE increased this score to reflect recent nosocomial decreased as the underlying risk abates. Discussion at Gold 21.12.20: For review at Mase recommendation	I Comments		
Discussion at Gold 13.11.20: Higher score required. Although the position has stabilised in so due to operational problems caused. Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. DE increase decreased as the underlying risk abates. Discussion at Gold 21.12.20: For review at Nosocomial Group on 22.12.20. Discussion at Gold 21.12.20: For review at Nosocomial Group on 22.12.20. Discussion at Gold Command 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold Command 24.1.21: Update provided for inclusion in log. Update given 25.01.21: 1. A Nosocomial Transmission Silver group has been established. A r Preventative measures are in place including testing on admission, segregating positive, susp to physical distancing. Audit tools developed to support consistency checking in key areas re: 2. An outbreak control team has been established to manage the outbreaks across the Health	me areas there are still outbreaks in new areas. For review sed this score to reflect recent nosocomial deaths and infect reduced to 20. hosocomial framework has been developed to focus on (a) p ected and negative patients, reinforcing PPE requirements, a PPE, physical distancing. Testing on admission dashboard	ions, however, this c revention and (b) re- and a focus on beha in use across all SD	sponse. viours relating

Discussion at Gold 1.2.21: Score to be reduced to 20 following discussion at Nosocomial Group.

Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Request review by the Nosocomial Group with a view to reducing the risk score.

Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. CW to review with the Nosocomial Group later this week. Recent deteriorations in position at Morriston and Singleton, although slight, may impact previous intention to reduce the score.

Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently.

To mitigate risks further, the Nosocomial Transmission Silver group has agreed an enhanced inpatient screening protocol within the emergency inpatient pathway, to include in addition to testing on day of admission, testing on Days 3 and 5 to identify clinically unrecognised positive patients sooner and ensure appropriate placement of positive patients in COVID wards. In addition, an inter-hospital screening protocol has been developed and is to be ratified by COVID Gold.

Mitigations have been reviewed this week, and although there has been an increase in protocols to be implemented, these have not yet embedded meaning that the score has not yet reduced. This reflects the current volatility of the situation.

Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. DE to consider potential to downgrade risk.

Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently. Given remaining outbreak areas, there is no requirement for the post-MA risk score to be reviewed, currently. Although the number of outbreak areas is declining, COVID patients are still arriving at sites from the community and it remains a case of admitting at risk to Singleton and Morriston.

Discussion at Gold 15.03.21: No alteration to post-MA risk score required currently. On review is there scope to downgrade in light of an improved position. Reported RE thinks same number of outbreaks reported to remain at this level.

Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Risk is still present.

Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently.

Discussion at Gold 12.04.21: No alteration to post-MA risk score required currently. PSD and CW to review narrative

Discussion at Gold 20.04.21: No alteration to post-MA risk score required currently. Risk has been considered over the last week and the risk score is to remain at 20 as a reflection of the, still, volatile situation and continued potential for escalation. Standing issues relate to staff and visitor testing, sustainable use of appropriate PPE and a slight delay to nosocomial reviews recently. PSD is to update narrative with a view to reducing the score if matters settle in the next 7-10 days.

Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently. Suggestion to manage via Quality & Safety Committee declined. Agreed to retain FAO of Gold given attention required on managing acute flow. This will not be addressed if managed by background IPC processes. The situation can change quickly. The risk has been reviewed this week and will be reconsidered in a fortnight.

Discussion at Gold 10.05.21: No alteration to post-MA risk score required currently. Improvements made in control measures, to review at the end of the week by Nosocomial Group. Discussion at Gold 17.05.21: Reviewed and updated in the log. Risk reduced to 16. Request by Pam Wenger for this risk to remain on C-19 risk register but also to be included as a risk on the Corporate risk register- SCORE REDUCED FROM 20 TO 16

Discussion at Gold 26.05.21: No alteration to post-MA risk score required

25	Current Risk Rating 4 x 4 = 16	
25		
16		
12		

Datix ID Number: 2522	R_COV_Strategic_018		
Risk: <u>Whole-Service Closure</u>	Director Lead: Chris White, Chief Operating Officer (000)	
Risk that services or facilities may not be able to function if there is a major incident or a rising	Assuring Committee: Gold Command COVID-19		
tide that renders current service models unable to operate	Date last reviewed: 20 TH April 2021		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)	
Sites have business continuity plans, however, there is a need to review the impact of one site	Action	Lead	Deadline
being overwhelmed by COVID demand. In particular, the impact of a closure of one or more	Business Continuity plans in place to be reviewed by	Singleton Group	Weekly
hospital front doors may require additional BC plans to be developed. Operational Silver will	operational silver command.	Director/Morriston	ongoing
review BC arrangements.		Service Director	
	Transferred to Health Board Risk Register		
Assurances	Gaps in assurance		
(How do we know if the things we are doing are having an impact?)	(What additional assurances should we seek?)		
Additional Co			
Discussion at Gold 29.10.20 - No alteration to post-MA risk score required currently. Discussion at Gold 06.11.20: No alteration to post-MA risk score required currently. Reflects risk of Discussion at Gold 13.11.20: No alteration to post-MA risk score required currently. KJ has circular Discussion at Gold 23.11.20: No alteration to post-MA risk score required currently. Awaiting revier Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 11.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Conversations at Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 29.03.21: No alterati	ated updated business continuity plan for Morriston ED. ew by DE, DL and JW. are ongoing re potential risk of whole-service closure. I KJ held a meeting and agreed a set of principles for this IA risk score required currently.	e. JW stated that this	is general,

rather than a COVID-specific one. Consideration to be made of whether this can be moved to the Service Group risk register and/or the corporate risk register. Discussion at Gold 26.04.21: No alteration to post-MA risk score required currently: Group agreed transfer of this risk to the Corporate Risk Register. Although the matter rose from COVID, it now relates to a more generic risk for pick-up at Health Board level. Agreement required re how this will be managed and by whom. Discussion at Gold 10.05.21: CLOSED and to transfer to Corporate Risk Register for monitoring by Chief Operating Officer. To follow up with RM regarding some outstanding information for the risk register.

		Current Risk Rating 5 x 4 = 20
Initial Risk	25	
Current	20	
Target	15	

Datix ID Number: 2567	R_COV_Strategic_019a		
Risk: Opening of Field Hospital (revised model - December 2020)	Director Lead: Rab McEwan, Chief Operating Officer	(COO)	
Risk of patient harm if the field hospital is opened without adequate assurance that the clinical	Assuring Committee: Gold Command COVID-19		
and workforce models are robust and that appropriate policies and procedures are in place	Date last reviewed: 24th May 2021		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)	
Full external assurance review undertaken and risks mitigated; separate risk log in place. Live			Deadline
exercise completed to test model and issues/actions picked up via FH Establishment group.	Live exercise completed to test model and	Director of	Weekly
Aim to undertake a 'soft launch' with a small number of patients to further test processes prior to	issues/actions picked up via FH Establishment group	Primary &	ongoing
arger scale activation - subject to staff availability. Following the Field Hospital Establishment		Community	
Group we have now deferred the planned soft launch due to staffing challenges during January 2021.		Services	
Soft launch held in abeyance subject to staffing and community risk.			
Assurances	Gaps in assurance		
How do we know if the things we are doing are having an impact?)	(What additional assurances should we seek?)		
Additional Co	mments		
Diale added 11 December 2020			
Risk added 11 December 2020			
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.			
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently.		. La characte	
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores repuired currently. Current scores repuired currently.		o last week.	
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores r Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.	s reflect discussion at Field Hospital Establishment Group	o last week.	
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores r Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.	s reflect discussion at Field Hospital Establishment Group vation)	o last week.	
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores reduces a Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently.		low likelihood a
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores r Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field here Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field here.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently.		low likelihood c
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores reduces a Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores reduces a Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field here. Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently with the field here.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently.		low likelihood c
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores reduces a Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. (Pending action Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field here Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently with the field here. Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of hat happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently.		low likelihood o
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores reduces a Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field he Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of hat happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using fi	eld hospitals, the	
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores reduces a Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field he Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently with the field he Discussion at Gold 08.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using five ssion at Gold 22.03.21: No alteration to post-MA risk sco	eld hospitals, the re required currer	ıtly.
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 12.21: No alteration to post-MA risk score required currently. Current scores reduised a Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field h Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field h Discussion at Gold 08.03.21: No alteration to post-MA risk score required currently with the field h Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of hat happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using five ssion at Gold 22.03.21: No alteration to post-MA risk sco	eld hospitals, the re required currer	ıtly.
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 12.21: No alteration to post-MA risk score required currently. Current scores reduised at Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. (Pending action Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field here Discussion at Gold 01.03.21: No alteration to post-MA risk score required. BO to consider review of hat happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score requi	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using five ssion at Gold 22.03.21: No alteration to post-MA risk sco e event of Morriston being affected to the point of closure	eld hospitals, the re required currer . JW stated that th	itly. nis is general,
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores rediscussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. (Pending active Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. (Pending active Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field he Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of that happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 29.03.21: No alteration to post-MA risk score required. Discussion at Gold 29.03.21: No alteration to post-MA risk score required.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using five ssion at Gold 22.03.21: No alteration to post-MA risk sco e event of Morriston being affected to the point of closure	eld hospitals, the re required currer . JW stated that th	itly. nis is general,
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. (Pending acti- Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field ho Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of that happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 29.03.21: No alteration to post-MA risk score required. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. On agenda for the perceived.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using fin ssion at Gold 22.03.21: No alteration to post-MA risk sco e event of Morriston being affected to the point of closure r consideration at this week's Field Hospital Establishmer	eld hospitals, the re required currer . JW stated that th	itly. his is general,
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores in Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Current scores in Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field he Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field he Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of that happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. For consideration by Field Hospital Establishment Group as mitigating actions are outdated. Discu XJ met with colleagues to produce a procedure which would enable redistribution of services in the emergency planning which should be in place as a matter of course. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. On agenda for o be received. Discussion at Gold 12.04.2021: No alteration to post-MA risk score required currently. For review I	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using five ssion at Gold 22.03.21: No alteration to post-MA risk sco e event of Morriston being affected to the point of closure ⁻ consideration at this week's Field Hospital Establishmer by the Field Hospital Establishment Group this week.	eld hospitals, the re required currer . JW stated that th nt Group. Subsequ	itly. nis is general,
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently. Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently. Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently. (Pending acti- Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field ho Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review of that happening at present may allow for the risk score to be reduced. Discussion at Gold 15.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 22.03.21: No alteration to post-MA risk score required. Discussion at Gold 29.03.21: No alteration to post-MA risk score required. Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. On agenda for the perceived.	s reflect discussion at Field Hospital Establishment Group vation) ospital unlikely to require activation imminently. of this, however, as although there is still a risk re using fin ssion at Gold 22.03.21: No alteration to post-MA risk sco e event of Morriston being affected to the point of closure r consideration at this week's Field Hospital Establishmer by the Field Hospital Establishment Group this week. y. Soft launch held in abeyance subject to staffing and co	eld hospitals, the re required currer . JW stated that th nt Group. Subsequ	itly. his is general,

SBU Health Board COVID-19 Risk Register – GOLD COMMAND – Last updated 21 June 20217 June 2021

15

12

Current

Target

Datix ID Number: 2568- CLOSED	R_COV_Strategic_019b		
Risk: <u>Opening of Field Hospital (revised model - December 2020)</u>	Director Lead: Rab McEwan, Chief Operating Officer	(COO)	
Risk of patient harm if the field hospital is opened without adequate assurance that the clinical	Assuring Committee: Gold Command COVID-19		
and workforce models are robust and that appropriate policies and procedures are in place	Date last reviewed: 26 TH April 2021		
Controls (What are we currently doing about the risk?)	Mitigating actions (What more s	hould we do?)	
WG governance checklist has been completed and a separate QIA developed to ensure that FH	Action	Lead	Deadline
model is robust.	WG governance checklist has been completed and a	Director of	Weekly
Aim to undertake a 'soft launch' with a small number of patients to further test processes prior to	separate QIA developed to ensure that FH model is	Primary &	ongoing
larger scale activation - subject to staff availability.	robust.	Community	
Following the Field Hospital Establishment Group we have now deferred the planned soft launch		Services	
due to staffing challenges during January 2021.			
Soft launch held in abeyance subject to staffing and community risk.	CLOSED		
Assurances (How do we know if the things we are doing are having an impact?)	Gaps in assurance (What additional assurances should we seek?)		
Additional Cor	monte		
Risk added 11 December 2020	liments		
Discussion at Gold 21.12.20: No alteration to post-MA risk score required currently.			
Discussion at Gold 7.1.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 24.1.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 1.2.21: No alteration to post-MA risk score required currently. Current scores re	eflect the situation in other parts of the sector		
Discussion at Gold 08.02.21: No alteration to post-MA risk score required currently. Current scores		last week	
Discussion at Gold 15.02.21: No alteration to post-MA risk score required currently.			
Discussion at Gold 22.02.21: No alteration to post-MA risk score required currently. (Pending activ	vation)		
Discussion at Gold 01.03.21: No alteration to post-MA risk score required currently with the field ho			
Discussion at Gold 08.03.21: No alteration to post-MA risk score required. BO to consider review o		eld hospitals, the lo	ow likelihood of
that happening at present may allow for the risk score to be reduced.			
Discussion at Gold 15.03.21: No alteration to post-MA risk score required. smaller scale soft openin	ng – Red 20 – change in likelihood of the requirement to	use this - To be k	ept under review
Discussion at Gold 22.03.21: No alteration to post-MA risk score required.	5 5 I		•
For consideration by Field Hospital Establishment Group as mitigating actions are outdated.			
Discussion at Gold 29.03.21: No alteration to post-MA risk score required currently. On agenda for	consideration at this week's Field Hospital Establishmer	t Group. Subseque	ent report-back
to be received.			
Discussion at Gold 12.04.2021: No alteration to post-MA risk score required currently. For review b	by the Field Hospital Establishment Group this week.		
Discussion at Gold 20.04.2021: Risk to be closed on the basis that the need for the soft launch test		pandemic. Should	d we see a ramp
up of prevalence or pressure on the system that suggests a ramp up to possible field hospital utilisation			
Discussion at Gold 26.04.2021			
Current Risk			
5 x 4 = 2	20		

Initial Risk	25
	20
Current	20
Target	15

R_COV_Strategic_020		
Director Lead: Chris White, Chief Operating Officer (COO) Assuring Committee: Gold Command COVID-19 Date last reviewed: 26 TH April 2021 Transferred to Health Board Risk Register		
Mitigating actions (What more should we do?)		
Action	Lead	Deadline
Additional Wellbeing support facilitated by limited L&D Coaches and Wellbeing team.	Director of Workforce	Weekly monitoring
Occupational Health open over the bank holidays to support staff testing, urgent advice giving and contact tracing.	Director of Workforce	Daily monitoring
Gaps in assurance (What additional assurances should we seek?)		
	Director Lead: Chris White, Chief Operating Officer (C Assuring Committee: Gold Command COVID-19 Date last reviewed: 26 TH April 2021 Transferred to Health Board Risk Register Mitigating actions (What more s Action Additional Wellbeing support facilitated by limited L&D Coaches and Wellbeing team. Occupational Health open over the bank holidays to support staff testing, urgent advice giving and contact tracing. Gaps in assurance	Director Lead: Chris White, Chief Operating Officer (COO) Assuring Committee: Gold Command COVID-19 Date last reviewed: 26 TH April 2021 Transferred to Health Board Risk Register Mitigating actions (What more should we do?) Action Lead Additional Wellbeing support facilitated by limited L&D Coaches and Wellbeing team. Director of Vorkforce Director of Support staff testing, urgent advice giving and contact tracing. Director of Gaps in assurance Vorkforce

For each risk identified, the LIKELIHOOD & CONSEQUENCE mechanism will be utilised. Essentially this examines each of the risks and attempts to assess the likelihood of the event occurring (PROBABLILITY) and the effect it could have on the Health Board (IMPACT). This process ensures that the Health Board will be focusing on those risks which require immediate attention rather than spending time on areas which are, relatively, a lower priority.

Risk Matrix	LIKELIHOOD (*)					
CONSEQUENCE (**)	1 - Rare	2 - Unlikely	3 - Possible	4 - Probable	5 - Expected	
1 - Negligible	1	2	3	4	5	
2 - Minor	2	4	6	8	10	
3 - Moderate	3	6	9	12	15	
4 - Major	4	8	12	16	20	
5 - Catastrophic	5	10	15	20	25	